Indication: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared with Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Relapsed/Refractory

Line of Therapy: 2nd Line

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: BeiGene, Ltd

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.